Amgen Launches Rituxan Rival In US
As Company Reflects On Future Of Biosimilars In US
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.
You may also be interested in...
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.